Adverse effects of reduced-dose d-penicillamine in children with mild-to-moderate lead poisoning.

Author: ShannonM W, TownsendM K

Paper Details 
Original Abstract of the Article :
Oral chelation therapy with d-penicillamine (d-PCN) has been proven to be effective in the treatment of mild-to-moderate lead poisoning. However, d-PCN is associated with a relatively high incidence of adverse effects when given in the standard dose of 25-30 mg/kg/d. Lower doses of d-PCN may reduce ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1345/aph.19084

データ提供:米国国立医学図書館(NLM)

D-Penicillamine for Lead Poisoning: Striking a Balance between Efficacy and Safety

This research delves into the use of d-penicillamine, a medication employed to treat lead poisoning, exploring the delicate balance between efficacy and safety. The researchers, like skilled pharmacists carefully weighing ingredients, examine the effectiveness of reduced-dose d-penicillamine in treating mild-to-moderate lead poisoning. They seek to optimize treatment strategies by minimizing the risk of adverse effects while maintaining the drug's effectiveness.

Finding the Sweet Spot: Reduced Dose, Reduced Risk

The study suggests that lower doses of d-penicillamine may be just as effective as standard doses, but with a significantly lower risk of adverse effects. It's like finding the perfect recipe, achieving the desired outcome with fewer ingredients and fewer potential side effects. The researchers emphasize the importance of carefully considering individual patient needs and adjusting treatment plans accordingly to strike the right balance between efficacy and safety.

Dr. Camel's Conclusion

This research underscores the importance of finding the optimal dosage and treatment strategies for medications like d-penicillamine. It emphasizes the need for individualized care and highlights the potential for reducing adverse effects while maintaining therapeutic benefits.

Date :
  1. Date Completed 2000-02-24
  2. Date Revised 2017-02-14
Further Info :

Pubmed ID

10669180

DOI: Digital Object Identifier

10.1345/aph.19084

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.